Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cadrenal Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Cadrenal Therapeutics, Inc.

CVKD

Cadrenal Therapeutics, Inc.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics develops novel anticoagulants targeting unmet needs in rare cardiovascular conditions. Its lead candidate, tecarfarin, is designed for patients with LVADs, ESKD, AFib, and thrombotic disorders, offering potentially more predictable anticoagulation. The company collaborates with Abbott on clinical trials, focusing on regulatory approval and commercialization of its targeted therapies for high-risk, underserved patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cadrenal Therapeutics, Inc.

1
1
Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Reports $2.5 Million Net Loss in Q1 2026, Seeks Additional Capital

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Reports $13.2 Million Net Loss and Plans for Future Funding

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Reports $10.2 Million Net Loss and Deteriorating Cash Position

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Reports Increased Net Loss and Operating Expenses for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Reports $3.8 Million Net Loss in Q1 2025, Increases Focus on Tecarfarin Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Reports $10.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cadrenal Therapeutics, Inc. Cadrenal Therapeutics Reports Significant Financial Decline in Q3 2024, Net Loss Increases

Via official filing (AI summary) | over 1 year ago | 0 comments